Safety of the allopurinol-mycophenolate mofetil combination in the treatment of hyperuricemia of kidney transplant recipients.
Navascués
Rafael A
RA
Gómez
Ernesto
E
Rodriguez
Minerva
M
Laures
Ana S
AS
Baltar
Jose
J
Grande
Jaime A
JA
D000328:Adult; D000493:Allopurinol / Q000009:adverse effects* / Q000627:therapeutic use; D016572:Cyclosporine / Q000009:adverse effects; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012307:Risk Factors; D014527:Uric Acid / Q000097:blood*
D007166:Immunosuppressive Agents; D014527:Uric Acid; D000493:Allopurinol; D016572:Cyclosporine; D009173:Mycophenolic Acid